[Recent advances in intraarterial chemotherapy in gynecologic malignancy].
Anti-cancer chemotherapy (CTX) agents are mainly given intravenously (i.v.) in patients with gynecologic malignancy. The reasons intraarterial chemotherapy (IA-CTX) are not more commonly used are the following: 1) cervical, corpus, and ovarian carcinoma have shown an appreciable response to i.v. cisplatin-based chemotherapy, 2) locally advanced carcinoma, suitable for IA-CTX, is a potentially systemic disease, 3) IA-CTX often requires a special technique, 4) IA-CTX has not been a major concern for the Gynecologic Oncology Group (GOG) in the United States, and 5) the very small amount of medical evidence supporting IA-CTX makes cancer patients hesitate to give informed consent prior to receiving IA-CTX. The major concern of gynecologic oncologists has already moved away from the administration route of agents to new agents themselves including paclitaxel, docetaxel, and CPT-11. Looking again at the clinical data of IA-CTX as a neoadjuvant CTX for advanced cervical carcinoma reported in the 1990s, the response rate seems to be superior to that achieved by i.v.-CTX. Thus, we must now reappraise the IA-CTX for gynecologic malignancy.
Shimizu
Yoshio
Y
Department of Gynecology, Cancer Institute Hospital, 1-37-1 Kami-ikebukuro, Toshima-ku, Tokyo 170-8455, Japan.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004621:Embolization, Therapeutic; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial; D020360:Neoadjuvant Therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy
D001761:Bleomycin; D002945:Cisplatin; D005472:Fluorouracil